Binds to the PU-box, a purine-rich DNA sequence (5'- GAGGAA-3') that can act as a lymphoid-specific enhancer. This protein is a transcriptional activator that may be specifically involved in the differentiation or activation of macrophages or B- cells. Also binds RNA and may modulate pre-mRNA splicing. Binds DNA as a monomer. Interacts with CEBPD and NONO. Interacts with RUNX1 and SPIB. Interacts with GFI1; the interaction represses SPI1 transcriptional activity. Highly expressed in both FV-P and FV-A-induced erythro- leukemia cell lines that have undergone rearrangements of the Spi- 1 gene due to the insertion of SFFV. Belongs to the ETS family. 2 isoforms of the human protein are produced by alternative splicing. Note: This description may include information from UniProtKB.
Protein type: DNA binding protein; Transcription factor
Chromosomal Location of Human Ortholog: 11p11.2
Cellular Component: nuclear chromatin
Molecular Function: RNA polymerase II transcription factor activity, enhancer binding; protein binding; NFAT protein binding; RNA binding; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; macrophage differentiation; granulocyte differentiation; somatic stem cell maintenance; positive regulation of transcription, DNA-dependent; myeloid dendritic cell differentiation; lymphoid progenitor cell differentiation; negative regulation of transcription from RNA polymerase II promoter; anatomical structure regression; regulation of transcription from RNA polymerase II promoter; regulation of erythrocyte differentiation; lymphocyte differentiation; negative regulation of gene expression, epigenetic; negative regulation of MHC class II biosynthetic process; erythrocyte differentiation; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.